Clinical Trial Update: Study of PD-1 Antibody Combined With Chemoradiotherapy in Oligometastatic Esophageal Cancer [Phase 2]

View source ↗

Summary

This Phase 2 trial evaluates a PD-1 antibody in combination with chemoradiotherapy for oligometastatic esophageal cancer and has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Esophageal Cancer

Drugs mentioned

• PD-1 antibody (PD-1 inhibitor)

Snippet

Sponsor: Cancer Institute and Hospital, Chinese Academy of Medical Sciences | Conditions: Esophagus Cancer, Chemoradiotherapy | Phase 2 | Status: COMPLETED